A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group, Dose Range Finding Study of JNJ-39758979 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2016
At a glance
- Drugs JNJ 39758979 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 30 Nov 2016 Status changed from discontinued to withdrawn prior to enrolment due to 2 cases of agranulocytosis in a different clinical trial with this same drug.
- 11 May 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.